BHC

LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).

Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.

Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 pursuant to which it will redeem approximately $643 million of aggregate principal amount of its outstanding 8.500% Senior Notes due 2027, CUSIP Nos. 91911XAW4 and U9098VAP7 (the "Notes"), using cash on hand.

LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares ("Common Shares") for a total aggregate purchase price of up to US$50 million (the "Share Repurchase Program"). The primary objective of the Share Repurchase Program is to manage the potential dilutive impact of future employee equity-based compensation.

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53% Consolidated Adjusted EBITDA Attributable to Bausch Health1 of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA1 growth, with 12% Reported and 8% Organic Revenue1 growth and 32% Adjusted EBITDA1 growth Net Income increased $205 million over the prior year Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations1 Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter. "Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth.

Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.